![\"Novo](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/02\/1770367582_376_b199128d4b2bbea4504ed4a2f3b29b4e.jpeg\")
Novo Nordisk A\/S <\/p>\n Novo Nordisk A\/S <\/p>\n
Bagsv\u00e6rd, Denmark and Plainsboro, NJ, 5 February 2026 \u2013 Novo Nordisk today issued the following statement regarding the announcement by Hims & Hers that they will unlawfully mass-market an unapproved, inauthentic, and untested knockoff semaglutide pill.<\/p>\n
\u201cThe action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety. Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the US gold-standard drug approval framework. This is another example of Hims & Hers’ historic behaviour of duping the American public with knock-off GLP-1 products, and the FDA has previously warned them about their deceptive advertising of GLP-1 knock-offs.<\/p>\n
The American Diabetes Association\u00ae\u2019s Obesity Association\u2122 recently published new standards of care, which\u00a0discourage\u00a0the use of compounded GLP-1s due to safety, quality, and effectiveness concerns.<\/p>\n
Only Novo Nordisk manufactures an FDA-approved\u00a0Wegovy\u00ae pill formulated with SNAC technology, which facilitates\u00a0semaglutide absorption when administered orally. \u00a0The Wegovy\u00ae pill is available in all doses, in full supply, nationwide in the US. Compounded semaglutide is not approved by the FDA and may contain impurities, unnecessary additives,\u00a0and untested doses.\u201d<\/p>\n
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com<\/a>, Facebook<\/a>, Instagram<\/a>, X<\/a>, LinkedIn<\/a> and YouTube<\/a>.<\/p>\n Contacts for further information:<\/p>\n Attachment<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S Bagsv\u00e6rd, Denmark and Plainsboro, NJ, 5 February 2026 \u2013 Novo Nordisk today issued the following…\n","protected":false},"author":2,"featured_media":585,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2641,997,1440,529,272],"class_list":{"0":"post-4051","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-american-diabetes-association","9":"tag-compounding","10":"tag-hims-hers","11":"tag-jacob-martin","12":"tag-novo-nordisk"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/4051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=4051"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/4051\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/585"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=4051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=4051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=4051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}